Highest-materiality recent filing
Tango Therapeutics appoints Robert Azelby to board; receives option for 35,910 shares at $27.97
Board expanded to seven directors; Azelby fills newly created vacancy as Class II director term expiring 2029.
Tango Therapeutics raises ~$566.5M in public offering to fund R&D and commercialization
Offering of 18,166,667 shares at $30.00/share and pre-funded warrants for 1,833,395 shares at $29.999/warrant.
Tango reports 92% ORR in PDAC with vopimetostat + daraxonrasib combo; plans Phase 3
92% ORR (11/12) in PDAC with vopimetostat + daraxonrasib; 90% 6-month PFS; 100% DCR.
Peters elected with 98,188,796 for; 17,623,596 withheld; Rothenberg with 92,476,172 for; 23,336,220 withheld.
Net loss $45.5M ($0.32/sh) vs $39.9M ($0.36/sh) YoY; R&D $33.5M, G&A $15.2M.
CFO Daniella Beckman ceased serving as principal financial officer effective April 15, 2026.
Tango Therapeutics appoints new CFO, additional execs to accelerate vopimetostat development
Daniella Beckman departs as CFO effective April 15; Matthew Gall named successor.
Net loss $38.7M for Q4 2025 ($0.29/share) vs $30.8M for Q4 2024; FY2025 net loss $101.6M vs $130.3M.
Barbara Weber, M.D. retires as President and CEO effective Jan 8, 2026; becomes Executive Chair through 2026.
Tango Therapeutics appoints Sung H. Lee to Board; grants option for 60k shares at $8.93
Board expanded to 8; Lee appointed as Class I director, term until 2028 annual meeting.
Tango Therapeutics enters $100M ATM offering with Leerink, terminates Jefferies ATM program
New $100M at-the-market common stock sales agreement with Leerink Partners as agent, dated Nov 21, 2025.
Net income $15.9M ($0.14 basic EPS) vs net loss $29.2M in Q3 2024; nine-month net loss $62.8M.
Tango Therapeutics raises ~$212M via registered direct offering and PIPE
Registered direct offering of 21.0M shares and 3.2M pre-funded warrants at $8.66; net proceeds ~$197M.
Tango Therapeutics discloses $152.8M cash; provides vopimetostat clinical update
Estimated cash, cash equivalents, and marketable securities of $152.8M as of Sept 30, 2025 (preliminary, unaudited).
Douglas Barry resigns as Chief Legal Officer and Corporate Secretary of Tango Therapeutics
Douglas Barry resigned as Chief Legal and Compliance Officer and Corporate Secretary effective September 12, 2025.
Tango Therapeutics Q2 net loss $38.9M ($0.35/sh); Gilead collab truncated
Net loss $38.9M ($0.35 per share) vs $25.6M ($0.24) in Q2 2024; revenue fell to $3.2M.
Tango Therapeutics shareholders approve doubling authorized shares to 400M, elect new director
Shareholders approved amendment to increase authorized common stock from 200M to 400M shares (85.8M for, 11M against).
Tango Therapeutics Q1 net loss $39.9M; cash runway extended to Q1 2027; TNG462 data update 2H2025
Net loss of $39.9M ($0.36/share) for Q1 2025 vs $37.9M ($0.35/share) in Q1 2024.
Tango Therapeutics reports Q4 2024 net loss of $37.7M; cash runway into 3Q 2026
Net loss of $37.7M for Q4 2024 ($0.35 per share) vs $30.8M loss in Q4 2023; full year net loss $130.3M ($1.19 per share).
Tango Therapeutics discloses $257.9M cash as of Dec 31, 2024
Cash, cash equivalents and marketable securities totaled $257.9M (unaudited).
Tango reports Q3 loss $29.2M; TNG462 shows durable activity; PRMT5 program advanced
TNG462 demonstrated clinical activity across multiple tumor types; 43% ORR in cholangiocarcinoma (n=7); median time on treatment 24 weeks and increasing.
Tango Therapeutics Q2 2024 net loss $25.6M; cash $322M, runway to 2027
Net loss $25.6M ($0.24/share) vs $20.7M loss ($0.23/share) in Q2 2023.
Shareholders approved amendment to Second Amended and Restated Certificate of Incorporation to limit officer liability under Delaware law (89.9M for, 5.5M against).
Tango Therapeutics discontinues TNG348 program due to liver toxicity in phase 1/2 trial
Phase 1/2 trial of TNG348, a USP1 inhibitor, terminated because of Grade 3/4 liver function abnormalities in patients on study >8 weeks.
Tango Therapeutics Q1 2024 net loss $37.9M ($0.35/sh); cash $343.6M funds into late 2026
Net loss of $37.9M, or $0.35 per share, vs $28.0M ($0.32) in Q1 2023.
Tango Therapeutics Q4 2023 net loss $30.8M; cash $336.9M; pipeline advances
Net loss Q4 2023 $30.8M ($0.32/sh); full year net loss $101.7M ($1.08/sh).
Tango Therapeutics reports $337M cash, $42M ATM proceeds, runway into late-2026
Cash, cash equivalents and marketable securities at Dec 31, 2023: $337M (unaudited).
Tango Q3 net loss $22.3M; cash $360M into 2026; TNG348 Fast Track
Cash, equivalents and marketable securities $359.9M at Sept 30, 2023; runway into 2026.
Tango Therapeutics director Aaron Davis resigns; John Ketchum appointed to board
Aaron Davis resigned from board effective Aug 28, 2023; no disagreement with management.
Tango Therapeutics raises $80M in PIPE financing at $5.15 per share
Gross proceeds of ~$80M from sale of ~15.5M shares/pre-funded warrants at $5.15/share.
Tango doses first patients in TNG462, TNG260 trials; CSO Alan Huang to depart; Q2 net loss narrows
First patient dosed in phase 1/2 of TNG462 (next-gen PRMT5 inhibitor) for MTAP-deleted tumors.
Tango Therapeutics stockholders elect two Class II directors and ratify PwC as auditor
Malte Peters, M.D. elected with 75,943,817 votes for, 3,532,483 withheld (5,145,731 broker non-votes).
Tango Therapeutics Q1 net loss $0.32/sh; cash $334M funds pipeline into 2026
Q1 net loss $28.0M ($0.32 per share) vs $25.2M ($0.29) in prior year; revenue flat at $5.8M.
Net loss of $29.1M in Q4 2022 ($0.33/share) vs $22.0M ($0.25) in Q4 2021; FY2022 net loss $108.2M ($1.23) vs $58.2M ($0.94).
Tango Therapeutics appoints Adam Crystal as President, R&D; base salary $550k, equity grants
Adam Crystal, M.D., Ph.D., appointed President, Research & Development, effective Feb 27, 2023.
Tango Therapeutics Q3 2022 net loss $29.1M; cash $393.3M; pipeline advances
Net loss $29.1M ($0.33/share) vs $19.6M ($0.28) year ago; cash $393.3M sufficient into 2025.
Tango Therapeutics Q2 2022 net loss $24.9M; TNG908 Orphan Drug Designation
Cash, cash equivalents and marketable securities $416.4M as of June 30, 2022.
Tango Therapeutics shareholders elect Calhoun and Huber as Class I directors, ratify PwC as auditor
Lesley Ann Calhoun elected with 74,549,730 votes for, 2,532,608 withheld, 4,658,458 broker non-votes.
Tango Therapeutics Q1 net loss $25.2M; cash $449.9M; TNG908 trial open
Net loss $25.2M ($0.29/share) vs $12.1M loss in Q1 2021; R&D expense $24.3M (+62% YoY).
Tango Therapeutics reports Q4 2021 net loss $22.0M; cash $485.3M; TNG908 Fast Track
Net loss Q4 2021: $22.0M ($0.25/share) vs $8.9M ($0.22/share) in Q4 2020; full year $58.2M ($0.94/share).
Tango Therapeutics Q3 2021 net loss $19.6M; cash $503.8M funds into H2 2024
Net loss of $19.6M ($0.28/share) vs $26.8M ($0.76) in Q3 2020; loss narrowed on revenue change.
Tango Therapeutics completes de-SPAC merger; starts trading on Nasdaq under TNGX
Merger closed Aug 10, 2021; Old Tango shares converted at ~0.34 share of new common stock per share.
the Board appointed Robert Azelby as a director of the Company to fill the newly created vacancy on the Board resulting from the increase to the board size.
Also on May 12, 2026, Kanishka Pothula resigned from the Board and as a member of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), in each case effective as of May 13, 2026.
the Board appointed Sung Lee as Lead Independent Director of the Board and the Chairperson of the Compensation Committee and as a member thereof, each effective as of May 13, 2026.
On May 12, 2026, Alexis Borisy resigned from the Company’s Board of Directors (the “Board”), as Lead Independent Director of the Board, and as the Chairperson of the Compensation Committee of the Board (the “Compensation Committee”) and as a member thereof, in each case effective as of May 13, 2026.
on April 10, 2026, the board of directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) determined that Daniella Beckman will no longer serve as the Company’s Chief Financial Officer, principal accounting officer and principal financial officer, effective as of April 15, 2026.
On August 28, 2023, Aaron Davis, a member of the Board of Directors of Tango Therapeutics, Inc. (the “Company”), serving as a Class III director, notified the Company that he is resigning from the Company’s Board of Directors (the “Board”), effective immediately.
Effective August 29, 2023, the Board appointed John Ketchum as a director of the Company to fill the newly created vacancy on the Board resulting from Mr. Davis’s resignation.
On August 3, 2023, Alan Huang, Ph.D., the Company's Chief Scientific Officer, notified the Company that he intends to transition out of his role as Chief Scientific Officer.
On February 28, 2023, Tango Therapeutics, Inc. (“Tango” or the “Company”) announced that Adam Crystal, M.D., Ph.D., 46 years old, was appointed as the Company’s President, Research & Development, effective as of February 27, 2023.
Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.
Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.
Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.
Max materiality 0.85 · Median 0.62 · Most common event earnings